INTRODUCTION
============

Malaria is a highly prevalent disease in the developing countries; annually there are about 300 million clinical cases and 1 million deaths worldwide \[[@b1-kjp-53-6-665]\]. Molecular heat shock protein (Hsp) has been highlighted as a novel anti-malarial target \[[@b2-kjp-53-6-665]\]. About 2% of *Plasmodium falciparum* encodes the genes for Hsp and a total of 95 genes coding for *P. falciparum* Hsp have been listed. However, only a small number of them have been characterized biochemically and functionally, and the roles of most Hsp are still uncovered in malaria \[[@b3-kjp-53-6-665],[@b4-kjp-53-6-665]\]. To date, Hsp40, Hsp70, and Hsp90 have been known to play essential roles in the development of *P. falciparum* parasites \[[@b5-kjp-53-6-665],[@b6-kjp-53-6-665]\]. Amongst these Hsps, Hsp90 has been well exploited as a potential target of anti-malarial drugs \[[@b7-kjp-53-6-665]\].

For many years, *P. falciparum* Hsp60 has been known to possess sequence similarity with that of the human or bacterial Hsp60 \[[@b8-kjp-53-6-665]\]. Typically, Hsp60 belongs to the family of type I chaperones in mitochondria and binds to various polypeptides, preventing their non-specific association for acquisition of native conformation \[[@b9-kjp-53-6-665]\]. However, the Hsp60 function as a molecular chaperone is still questionable in *P. falciparum*. A few of Hsp60 genes have been identified from protozoan parasites such as *Entamoeba histolytica* \[[@b10-kjp-53-6-665]\], *Brugia malayi* \[[@b11-kjp-53-6-665]\], and *Trichomonas vaginalis* \[[@b12-kjp-53-6-665]\]. The high level of transcript Hsp60 from *P. falciparum* was identified in blood stage parasites, and the localization of *Plasmodium* Hsp60 was identified in the mitochondrion and apical complex in *P. falciparum* \[[@b3-kjp-53-6-665],[@b13-kjp-53-6-665]\]. Apart from functioning as a typical mitochondrial molecular chaperone, Hsp60 has also been detected in the cytosol, cell surface, extracellular space, and biological fluids, indicating the potential extramitochondrial activities of mitochondrial Hsp60 \[[@b14-kjp-53-6-665]-[@b17-kjp-53-6-665]\]. According to the system analysis of Hsp networks in *P. falciparum* based on PlasmoDB, the hypothetical associative proteases were predicted as cysteine proteases which are involved in hemoglobin metabolism \[[@b3-kjp-53-6-665],[@b18-kjp-53-6-665]\]. Therefore, it would be an imperative study to investigate the correlation between Hsprelated networks with focusing on proteases.

*Plasmodium* actively expresses about 100 proteases during the intra-erythrocytic stages of parasite development \[[@b19-kjp-53-6-665],[@b20-kjp-53-6-665]\]. Among various malaria proteases, cysteine protease falcipain and aspartic protease plasmepsin catalyze hemoglobin as nutrient in the parasite food vacuole (FV) \[[@b21-kjp-53-6-665]\]. Plasmepsin IV is localized in FV and plasmepsin V is excluded from the FV in malaria \[[@b22-kjp-53-6-665]\]. Endogenous expression of *Plasmodium* calpain has been profiled along the asexual cycle \[[@b23-kjp-53-6-665],[@b24-kjp-53-6-665]\]. In our previous study, *Plasmodium* calpain was confirmed to play a role in degradation of hemoglobin and activate plasmepsin IV \[[@b25-kjp-53-6-665]\]. However, the role of *Plasmodium* calpain networks is still questionable. Despite a system analysis of the potential networks between *P. falciparum* Hsp and cysteine proteases \[[@b18-kjp-53-6-665]\], relevance of *Plasmodium* calpain and Hsps has not been understood.

Mammalian Hsp60 has been reported to be inhibited by mizoribine \[[@b26-kjp-53-6-665]\]. However, there is no report of anti-malarial activity of mizoribine yet. In this study, we extended the studies with activity of *P. falciparum* Hsp60 on *P. falciparum* calpain, using mizoribine as an Hsp60 inhibitor. To reveal the activity of *P. falciparum* Hsp60 on *P. falciparum* calpain, in vitro interaction and subcellular co-location of *P. falciparum* Hsp60 and *P. falciparum* calpain were determined, and the inhibitory effect of Hsp60 inhibitor on *Pf*-calpain activity and *P. falciparum* growth was determined.

MATERIALS AND METHODS
=====================

Antibodies
----------

The rabbit polyclonal *P. falciparum* (*Pf*)-Hsp60 antibody was purchased from LSBio (Seattle, Washington, USA). The rabbit polyclonal anti-*Pf*-calpain was generated as described in a previous study \[[@b27-kjp-53-6-665]\]. Antisera against GroEL raised in mice were generated in this study. The secondary goat-anti-rabbit IgG conjugated with horseradish peroxidase (HRP) was purchased from Bio-Rad (Hercules, California, USA). Cy5-conjugated goat-anti-rabbit IgG, FITC-conjugated rabbit-anti-mouse IgG, and anti-GAPDH antibody produced in rabbits were purchased from Sigma-Aldrich (St. Louis, Missouri, USA).

Reagents
--------

Percoll was purchased from Amersham Pharmacia Biotech (Uppsala, Sweden). Mizoribine and N-Acetyl-L-leucyl-L-leucyl-L-norleucinal (ALLN) were purchased from Sigma-Aldrich. SYTOX^®^ Green Nucleic Acid Stain was purchased from Life Technologies (Carlsbad, California, USA).

In vitro culture of *P. falciparum*
-----------------------------------

*P. falciparum* 3D7 (ATCC PRA-405D) strain was purchased from ATCC (Manassas, Virginia, USA) and kept at -80˚C as frozen stocks. This 3D7 strain was grown in human erythrocytes, as described previously \[[@b28-kjp-53-6-665]\]. Briefly, parasites were maintained in continuous culture with 5% hematocrit of type O human red blood cells suspended in RPMI 1640 medium supplemented with 24 mM sodium bicarbonate, 25 mM HEPES, 0.8% hypoxanthine, 0.9% albumax, and 25 µg/ml gentamycin. The 6-well plates were placed in an incubator (5% CO~2~, 5% O~2~, and 90% N~2~ atmosphere) at 37˚C, and the medium was changed daily when parasitemia reached at least 5%. The parasite density was determined by Giemsa staining of thin smears as a percentage of infected erythrocytes in fields of total 500 erythrocytes.

Isolation of the infected RBC
-----------------------------

To obtain the parasite-infected RBC, *P. falciparum* cultures were centrifuged, and each 1 ml of iRBC pellet in PBS was carefully placed on top of 3 ml of 70% Percoll gradient (v/v) \[[@b29-kjp-53-6-665]\]. Each tube was centrifuged at 800 g for 10 min and stopped with deceleration 0. The interface layer containing the infected RBCs was washed 2 times with complete media to make a pellet.

Western blot analysis
---------------------

The identification of *Pf*-Hsp60 and *Pf*-calpains was confirmed by western analysis. The pellet of the infected RBCs were resuspended with RIPA lysis buffer (150 mM NaCl, 50 mM Tris--HCl pH 7.6, 0.1% NP-40, and protease inhibitor cocktail) (Pierce, Waltham, Massachusetts, USA). To detect the existence of *Pf*-Hsp60 and *Pf*-calpains, 500 µg proteins were used for SDS-PAGE. Besides, GroEL protein was electrophoresed with polyacrylamide gel and transferred onto a PVDF membrane. The membrane was blocked with 5% skim milk and incubated with either anti-*Pf*-Hsp60 (1:4,000 dilution) or anti-*Pf*-calpain (1:2,000 dilution). The blots were further incubated with goat anti-rabbit IgG conjugated-HRP antibodies for 1 hr (1:5,000 dilution).

Immunoprecipitation analysis
----------------------------

The eluted proteins and parasite-infected RBCs were resuspended in native lysis buffer, i.e., 20 mM Tris HCl pH 8.0, 137 mM NaCl, 10% glycerol, 1% Nonidet P-40 (NP-40), 2 mM EDTA, and a 500 µg protein was mixed with 10 µg of anti-*Pf*-Hsp60 for overnight at 4˚C on a rocking platform. Next day, 50 µl of Dynabead Protein A (Invitrogen, Carlsbad, California, USA) were added to antigen-antibody complex, and this binding was allowed to proceed for 4 hr. Finally, the immunoprecipitate was then collected by adding 0.1 M citrate (pH 2.5) to antigen-antibody bead complex for 2 min. SDS-PAGE was performed, and the protein was transferred onto a PVDF membrane. The blot was analysed with anti-*Pf*-calpain (1:100 dilution) and anti-*Pf*-Hsp60 (1:2,000 dilution). Negative control sample was prepared with anti-rabbit IgG for specificity of immunoprecipitation.

Immunofluorescence assay
------------------------

To investigate the localization of *Pf*-calpain and GroEL-like protein, immunofluorescence assay (IFA) was carried out as previously described \[[@b24-kjp-53-6-665]\]. As co-localization requires 2 antibodies generated in different species, anti-GroEL generated in mice was used for IFA with anti-*Pf*-calpain produced in rabbits instead of anti-*Pf*-Hsp60 produced in rabbits. The infected RBCs were smeared on a coverslip and dried completely overnight. Following fixation of parasite-infected red blood cells by 1% paraformaldehyde, the presence of each protein was examined using anti-*Pf*-calpain and anti-GroEL as the primary antibody (1:200 dilution). Subsequent to washing, the erythrocytes were incubated with Cy5-conjugated goat anti-rabbit IgG secondary antibodies and FITC-conjugated rabbit anti-mouse IgG secondary antibodies (1:400 dilution) for 1 hr at room temperature. After washing with PBS, a cover slip was mounted on the slide with mounting media including 4\', 6-diamidino-2-phenylindole (DAPI) (Vector, Burlingame, California, USA). The images of fluorescent erythrocytes were visualized by 510 Meta Confocal Laser Scanning Microscope (LSM) (Carl Zeiss, Jena, Germany) using a 1,000× oil immersion objective. The images were processed using LSM viewer. As negative control, rabbit IgG and antisera of mice were used to validate the specificity of the fluorescence signal.

Measurement of calpain activity using fluorogenic substrate assay
-----------------------------------------------------------------

To determine the effect of mizoribine on malarial calpain activity, the infected RBCs were lysed in 0.01% saponin/PBS solution, and the proteolytic activity was assessed employing fluorogenic substrate, Succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC) (Bachem, Torrance, California, USA) as described previously \[[@b27-kjp-53-6-665],[@b28-kjp-53-6-665]\]. Briefly, the isolated RBC lysates were incubated with the serially diluted inhibitors for 1 hr at 37˚C in the presence of MOPs buffer (116 mM NaCl, 5.4 mM KCl, 0.8 mM MgSO~4~, 5.5 mM D-glucose, 50 mM MOPS, and 1 mM CaCl~2~, pH 7.2). The proteolytic activity was monitored at 30 min after addition of the substrate. The wavelengths of the Infinite F200 fluorometer (Tecan, Männedorf, Switzerland) were set to excitation at 360 nm and emission at 460 nm. The percentage was plotted against the log of the inhibitor concentration using GraphPad Prism 5.0.

In vitro antimalarial activity of mizoribine
--------------------------------------------

To access the effect of mizoribine on malarial growth, 0.5% parasite density in 2% hemocirt was seeded onto a 48-well plate, and mizoribine was serially diluted in media for 48 hr without any medium change. At last, 100 µl of *P. falciparum* cultures were taken out from each well of 48-well plate, and 1 µl of blood pellet was mixed with 5 mM of SYTOX green solution to obtain a final volume of 1.5 ml. The mixture solution was left in dark for 30 min at room temperature, and the anti-malarial activity of mizoribine was analyzed by FACS^TM^ Calibur Flow cytometer (BD Biosciences, Carlsbad, California, USA).

RESULTS
=======

Sequence analysis of *P. falciparum* Hsp60
------------------------------------------

As Hsp families are conserved in most organisms from bacteria to higher eukaryotes, the sequences of Hsp60 is conserved among bacteria, parasites, plants, and humans \[[@b8-kjp-53-6-665]\]. As shown in [Fig. 1A](#f1-kjp-53-6-665){ref-type="fig"}, full-length sequences of *Plasmodium* Hsp60 (1-577 amino acids) were aligned in BLAST, using BLASTP 2.2.29+ program. It shows 93-100% identities among 5 *Plasmodium* species, i.e., *P. falciparum* (GenBank accession no. AAC47716.1), *P. knowlesi* (no. XP_002258797.1), *P. berghei* (no. XP_677968.1), *P. yoelii* (no. AAC78151.1), and *P. reichenowi* (no. CDO64587.1)\]. In contrast, *Pf*-Hsp60 shows 72%/88%, 51%/70%, 55%/75%, 54%/72%, 59%/79%, 54%/73% identities/positives for *Toxoplasma gondii* Hsp60 (no. XP_002367122.1), *Trichomonas vaginalis* Hsp60 (no. AAB39487.1), *Legionella pneumophila* Hsp60 (no. ACI47229.1), *Arabidopsis thaliana* Hsp60 (no. AEE76842.1), and *Homo sapiens* Hsp60 (no. NP_955472.1). Based on domain analysis tool of European Bioinformatics Institute, GroEL-like equatorial domains (30-216 and 397-546 amino acids) (red squares) and GroEL-like apical domains (214-403 amino acids) (blue squares) were highly conserved among 5 *Plasmodium* species Hsp60. In this study, *Oleispira antarctica* GroEL (UniProtKB accession n. Q8KM30) was extracted from *Escherichia coli* strain Arctic Express, and the antigenicity of anti-*Pf*-Hsp60 against GroEL was confirmed by western blot analysis. GroEL was detected by anti-*Pf*-Hsp60 in a dose-dependent matter, supporting the high homology (54%/72% identities/positives) between GroEL and *Pf*-Hsp60 ([Fig. 1B](#f1-kjp-53-6-665){ref-type="fig"}). Alignment results among different species Hsp60 were summarized in [Table 1](#t1-kjp-53-6-665){ref-type="table"}. Because of 54%/73% identities/positives between human -and *Pf*-Hsp60, it was indispensable to separate the infected RBCs in our study. To verify the purities of iRBC after purification by Percoll gradient, the smeared *P. falciparum* was examined by microscopy after Giemsa staining. As shown in [Fig. 2](#f2-kjp-53-6-665){ref-type="fig"}, RBCs obtained from the interface layer was confirmed to include only the infected RBCs, and the pellet included the uninfected RBCs, indicating that the Percoll isolation method was suitable for separating the infected RBCs from the total RBC population.

Expression of *Pf*-Hsp60 and *Pf*-calpain in the infected RBCs
--------------------------------------------------------------

To address the endogenous *Pf*-Hsp60 and *Pf*-calpain, immunoblotting analysis was performed. The parasite density was about 13% within 6 days. After isolation of the infected RBCs, 500 µg of lysates were electrophoresed on SDS-PAGE. The expression of *Pf*-Hsp60 (60 kDa), GroEL like protein (60 kDa), and *Pf*-calpain (240 kDa) in the infected RBC lysates were shown as dominant protein molecular weight ([Fig. 3A](#f3-kjp-53-6-665){ref-type="fig"}). *Plasmodium* Hsp60 was confirmed in cell lysates of *P. falciparum* 3D7. Besides, anti-GroEL reacted with 60 kDa of the protein, and anti-*Pf*-Hsp60 reacted to the same size in the infected RBC lysates, indicating the possibility that anti-GroEL could be useful for detection of *Pf*-Hsp60 in malaria. Finally, the potential complex between *Plasmodium* Hsp60 and *Plasmodium* calpain was confirmed by immunoprecipitation using anti-*Pf*-calpain in cell lysates, and the eluent showed the presence of *Pf*-Hsp60 by anti-Hsp60 ([Fig. 3B](#f3-kjp-53-6-665){ref-type="fig"}). Subcellular localization of *Pf*-calpain, *Pf*-Hsp60 was determined by IFA. GroEL-like protein and *Pf*-calpain appeared in both trophozoites ([Fig. 4A](#f4-kjp-53-6-665){ref-type="fig"}) and schizonts ([Fig. 4B](#f4-kjp-53-6-665){ref-type="fig"}). The potential co-localization of GroEL-like protein and *Pf*-calpain were analyzed by merging 2 images, and those signals appeared to be partially co-localized in both trophozoites and schizonts.

Interference of mizoribine on calpain activity in *P. falciparum*
-----------------------------------------------------------------

We also explored the inhibition rate of endogenous *Pf*-calpain activity by mizoribine. Typically, 10 µg of lysate was reacted with serially diluted mizoribine at 37˚C for 60 min. Consecutively, 10 µM of substrate was added to the mixture of lysate and the serially diluted mizoribine for 37˚C for 30 min further. As seen in [Fig. 5](#f5-kjp-53-6-665){ref-type="fig"}, mizoribine suppressed the calpain enzyme activity up to 40% at a concentration of more than 80 µM. ALLN was used as the positive control of anti-calpain reagent.

In vitro inhibition of mizoribine on malarial growth
----------------------------------------------------

The in vitro efficacy of mizoribine on malarial growth was evaluated. After treatment with mizoribine for 2 days, the growth of *P. falciparum* was evaluated by flow cytometry. IC~50\ (growth)~ of mizoribine was 68.13 µM. IC~50\ (growth)~ of ALLN was 0.16 µM which is a 455-fold potent reagent in comparison to mizoribine ([Fig. 6](#f6-kjp-53-6-665){ref-type="fig"}).

DISCUSSION
==========

The sudden changes in environment including nutrient deprivation, elevated temperature, low pH, increase in heavy metal ions, and increased parasitic infections are related to Hsp expression \[[@b6-kjp-53-6-665]\]. In addition to typical function of Hsps such as folding/unfolding/assembly of protein, transporting protein to adequate subcellular compartment, and signaling, *Pf*-Hsp has played a pivotal role in modulating the activity of antioxidant enzymes in parasites \[[@b13-kjp-53-6-665]\]. An increase in mRNA level of *Plasmodium* Hsps at the ring stage was noted, which continued up to the trophozoite stage and declined at schizonts \[[@b23-kjp-53-6-665]\]. This observation possibly indicates massive Hsp may participate in orchestration of malarial protein networks during its maturation \[[@b18-kjp-53-6-665]\]. In our IFA study, the fluorescence level of Hsp60 confirmed by anti-GroEL showed that it was potentially co-localized with *Pf*-calpain at the trophozoite stage but detected widely at the schizont stage.

Malarial parasites should possess an efficient and highly specific protease system for massive hemoglobin proteolysis \[[@b30-kjp-53-6-665]\]. As one of the efficient malarial proteases, malarial calpain was found to activate plasmepsin IV and degrade hemoglobin in our previous study \[[@b25-kjp-53-6-665]\]. However, the *Pf*-calpain-related pathway was uncertain in the infected RBCs. In this study, the role of Hsp60 on *Pf*-calpain was evaluated to determine the relevance of Hsp60 on cysteine protease activity, leading to impairment of malarial growth. First, *Pf*-calpain protein level in the infected RBC was determined by western blot analysis but during immunoprecipitation *Pf*-calpain protein was diffused in a relatively low amount of lysate, indicating an easy degradation of *Pf*-calpain protein. Because subcellular locations of Hsps have been implicating a Hsp-associated event, these IFA findings allowed us to test the influence of Hsp on *Pf*-calpain activity.

Currently, mizoribine is known as an effective drug in antitumor therapy as it targets Hsp60 \[[@b26-kjp-53-6-665]\]; however, there are no challenging reports on the inhibitor of Hsp60 as novel anti-malarial candidate yet. As a result of testing mizoribine, the inhibitory concentrations of mizoribine for *Pf*-calpain activity and malarial growth were higher than those of ALLN, a typical calpain inhibitor, supporting the above data of the partial relevance of Hsp60 on *Pf*-calpain activity. Hsp60 is known to form various complexes \[[@b31-kjp-53-6-665]\]. Therefore, the multiple-Hsp complex may be implicated in the *Pf*-calpain activity. A novel Hsp (28-kDa) has been reported to belong to a malarial metalloprotease in *P. vivax* \[[@b32-kjp-53-6-665]\] but there is no report on the relevance of any *Pf*-Hsp on *Pf*-calpain activity. In the present study, a potential network between *Pf*-Hsp60 and malaria *Pf*-calpain was revealed, and the combined inhibitors of multiple Hsps would elucidate further Hsp networks of *P. falciparum* maturation and survival. Although *Pf*-Hsp60 could be associated with *Pf*-calpain activity, mizoribine was less effective than ALLN on *Pf*-calpain and malaria growth. These results indicate a potential relevance between *Pf*-Hsp60 and *Pf*-calpain network, and other factors could be involved in this association. We believe in that highlighting the further networks of *Pf*-Hsps and cysteine proteases would be one of better understandings to develop anti-malarial candidate.
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![Multiple sequence alignment of Hsp60s derived from different species. (A) Five Hsp60s derived from different *Plasmodium* species were aligned with those of 6 non-*Plasmodium* species. Identical residues are shaded in black while similar amino acids are shown in gray background. GroEL-like equatorial domains (red square) and GroEL-like apical domain (blue square) are shown. (B) Immunoblotting (IB) was performed to detect GroEL with anti-*Pf*-Hsp60.](kjp-53-6-665f1){#f1-kjp-53-6-665}

![Purification of *P. falciparum*. Total RBC (A) was purified using 70% Percoll and separated into only infected RBCs (iRBC) (B) at interface layer and pellet (C). Giemsa stain was performed and interface cells were confirmed as the schizonts under a microscope.](kjp-53-6-665f2){#f2-kjp-53-6-665}

![Interaction of *Plasmodium* Hsp60 and *Plasmodium* calpain in the infected RBCs. After isolation of *P. falciparum* (*Pf*)-infected RBC (iRBC), the presence of endogenous *Pf*-Hsp60, GroEL like protein, and *Pf*-calpain was confirmed by immunoblotting (IB) analysis in uninfected (U) and infected (I) RBC (A). Each GroEL like protein, *Pf*-Hsp60, and *Pf*-calpain in iRBC were detected dominantly. Immunoprecipitation (IP) was performed to determine the interaction between *Plasmodium* Hsp60 and *Plasmodium* calpain. Lysate (500 μg) of iRBC was immunoprecipitated with anti-*Pf*-calpin and the presence of *Pf*-Hsp60 in the eluent was confirmed by IB, using anti-*Pf*-Hsp60 (B).](kjp-53-6-665f3){#f3-kjp-53-6-665}

![Localization of *Pf*-Hsp60 and *Pf*-calpain in the infected RBCs. Co-localization of *Pf*-Hsp60 and *Pf*-calpain was observed by IFA. Anti-GroEL-antibody was used for detection of *Pf*-Hsp60 using FITC-conjugated rabbit-anti-mouse IgG (green). *Pf*-calpain was visualized by Cy5-conjugated goat-anti-rabbit IgG (red). *Pf*-Hsp60 was partially co-localized (yellow) with *Pf*-calpan in both trophozoites (A) and schizonts (B).](kjp-53-6-665f4){#f4-kjp-53-6-665}

![Interference of mizoribine on *Pf*-calpain activity. After isolation of the infected RBCs. the proteolytic activity of *Pf*-calpain was assessed by fluorogenic substrate, Suc-LLVY-AMC in the presence of ALLN (A) or Mizoribine (B). ALLN and Mizoribine suppressed the calpain enzyme activity in dose-dependent matter.](kjp-53-6-665f5){#f5-kjp-53-6-665}

![Anti-malarial effect of mizoribine. *P. falciparum* was cultured in the presence of ALLN or mizoribine in vitro. After treatment of inhibitors for 2 days, the parasite density of *P. falciparum* was analyzed by flow cytometer. Each IC~50~ (growth) of ALLN (A) and mizoribine (B) was determined by plotting in Graphpad Prism software.](kjp-53-6-665f6){#f6-kjp-53-6-665}

###### 

Analysis of Hsp60 identities derived from different species

  Species            Identities (%)    Positives (%)     Gaps (%)       GenBank accession no.
  ------------------ ----------------- ----------------- -------------- -----------------------
  *P. falciparum*    577/577 (100.0)   577/577 (100.0)   0/577 (0.0)     AAC47716.1
  *P. knowlesi*      545/580 (94.0)    564/580 (97.2)    3/580 (0.5)     XP_002258797.1
  *P. berghei*       541/580 (93.3)    558/580 (96.2)    4/580 (0.7)     XP_677968.1
  *P. yoelii*        539/580 (92.9)    557/580 (96.0)    4/580 (0.7)     AAC78151.1
  *P. reichenowi*    574/580 (99.0)    576/580 (99.3)    3/580 (0.5)     CDO64587.1
  *T. gondii*        383/532 (72.0)    469/532 (88.2)    4/532 (0.8)     XP_002367122.1
  *T. vaginalis*     280/549 (51.0)    387/549 (70.5)    11/549 (2.0)    AAB39487.1
  *L. pneumophila*   293/532 (55.1)    400/532 (75.2)    7/532 (1.3)     ACI47229.1
  *O. antarctica*    283/525 (53.9)    381/525 (72.6)    10/525 (1.9)    Q8KM30
  *A. thaliana*      313/530 (59.1)    422/530 (79.6)    4/530 (0.0)     AEE76842.1
  *H. sapiens*       290/535 (54.2)    395/535 (73.8)    6/535 (1.1)     NP_955472.1
